Hypofractionation for prostate cancer: a critical review

Area of Science:

• Radiation Oncology
• Medical Physics
• Prostate Cancer Research

Background:

• Radiotherapy fractionation should align with tumor and normal tissue sensitivity (alpha-beta ratio).
• Recent studies suggest a low alpha-beta ratio (1-3 Gy) for prostate cancer.
• A low alpha-beta ratio theoretically favors hypofractionation for improved therapeutic ratio.

Purpose of the Study:

• To critically review clinical experience with hypofractionated radiotherapy for prostate cancer.
• To evaluate the current evidence supporting the hypothesis of a low alpha-beta ratio in prostate cancer.
• To discuss ongoing randomized trials investigating hypofractionation efficacy and safety.

Main Methods:

• Critical review of existing prospective trials and clinical experience with hypofractionation.
• Analysis of data regarding toxicity and efficacy in hypofractionated prostate cancer treatment.
• Description of ongoing large randomized trials comparing conventional versus hypofractionated schedules.

Main Results:

• Prospective trials suggest limited toxicity with advanced dose delivery and precise margins in hypofractionation.
• The single-arm nature of current trials restricts definitive conclusions on treatment efficacy.
• Several large randomized trials are underway to provide more robust efficacy and safety data.

Conclusions:

• The hypothesis of a low alpha-beta ratio for prostate cancer remains unconfirmed.
• Definitive statements on the efficacy of hypofractionation await results from ongoing randomized trials.
• Further rigorous peer review of completed trial data is necessary to establish optimal fractionation strategies.